Stocktoria
Eisai Co., Ltd. 4523.T
JP · Tokyo Stock Exchange · XTKS · stock · Healthcare · website
Eisai Co., Ltd. financials (annual, from 10-K)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ¥825.4B | ¥789.4B | ¥741.8B | ¥744.4B |
| Gross profit | ¥634.2B | ¥620.6B | ¥586.4B | ¥566.6B |
| R&D expense | ¥158.7B | ¥171.6B | ¥169.0B | ¥173.0B |
| SG&A expense | ¥435.3B | ¥408.0B | ¥374.4B | ¥358.3B |
| Operating income | ¥44.1B | ¥54.4B | ¥53.4B | ¥40.0B |
| Interest expense | ¥5.3B | ¥3.5B | ¥2.4B | ¥2.3B |
| Income tax | ¥10.5B | ¥13.0B | ¥18.0B | -¥11.8B |
| Net income | ¥38.6B | ¥46.4B | ¥42.4B | ¥55.4B |
| EPS (diluted) | ¥136.78 | ¥163.76 | ¥147.86 | ¥193.31 |
| Operating cash flow | ¥61.3B | ¥30.1B | ¥56.0B | -¥1.8B |
| Free cash flow | ¥20.2B | ¥7.1B | ¥31.2B | -¥36.3B |
| Cash & equivalents | ¥245.4B | ¥265.6B | ¥304.7B | ¥267.4B |
| Inventory | ¥257.5B | ¥215.9B | ¥174.7B | ¥140.4B |
| Total assets | ¥1.45T | ¥1.39T | ¥1.39T | ¥1.26T |
| Total liabilities | ¥524.0B | ¥520.6B | ¥494.8B | ¥440.8B |
| Shareholders' equity | ¥899.0B | ¥841.4B | ¥875.6B | ¥800.0B |
Growth · year-over-year · Revenue CAGR 3.5%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +4.6% | +6.4% | -0.4% | — |
| Net income growth | -17.0% | +9.5% | -23.5% | — |
| EPS growth | -16.5% | +10.8% | -23.5% | — |
| Free cash flow growth | +182.0% | -77.1% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · JP · as of 2026-03-31. Figures in JPY; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.